148 related articles for article (PubMed ID: 34147284)
21. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer.
Tozzi R; Casarin J; Baysal A; Valenti G; Kilic Y; Majd HS; Morotti M
J Gynecol Oncol; 2019 Mar; 30(2):e25. PubMed ID: 30740956
[TBL] [Abstract][Full Text] [Related]
22. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
23. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
24. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
Plett H; Filippova OT; Garbi A; Kommoss S; Rosendahl M; Langstraat C; Phadnis S; Muallem MZ; Baert T; Chi DS; Aletti GD; Taran FA; Ramspott JP; Zivanovic O; du Bois A; Sonoda Y; Gardner G; Traut A; Roche KL; Harter P
Gynecol Oncol; 2020 Nov; 159(2):434-441. PubMed ID: 32919778
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
26. Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer.
Angeles MA; Cabarrou B; Gil-Moreno A; Pérez-Benavente A; Spagnolo E; Rychlik A; Martínez-Gómez C; Guyon F; Zapardiel I; Querleu D; Illac C; Migliorelli F; Bétrian S; Ferron G; Hernández A; Martinez A
J Gynecol Oncol; 2021 Nov; 32(6):e78. PubMed ID: 34431252
[TBL] [Abstract][Full Text] [Related]
27. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Boerner T; Filippova OT; Chi AJ; Iasonos A; Zhou QC; Long Roche K; Zivanovic O; Park BJ; Huang J; Jones DR; Abu-Rustum NR; Gardner G; Sonoda Y; Chi DS
Gynecol Oncol; 2020 Oct; 159(1):66-71. PubMed ID: 32792282
[TBL] [Abstract][Full Text] [Related]
28. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.
Sehouli J; Savvatis K; Braicu EI; Schmidt SC; Lichtenegger W; Fotopoulou C
Int J Gynecol Cancer; 2010 Nov; 20(8):1331-40. PubMed ID: 21051973
[TBL] [Abstract][Full Text] [Related]
29. Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
Jiang C; Li Z
Gynecol Oncol; 2021 Aug; 162(2):339-344. PubMed ID: 34147283
[TBL] [Abstract][Full Text] [Related]
30. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study.
Dahm-Kähler P; Palmqvist C; Staf C; Holmberg E; Johannesson L
Gynecol Oncol; 2016 Aug; 142(2):211-6. PubMed ID: 27238084
[TBL] [Abstract][Full Text] [Related]
31. Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.
Narasimhulu DM; Thannickal A; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2021 Mar; 160(3):681-687. PubMed ID: 33390326
[TBL] [Abstract][Full Text] [Related]
32. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis.
Chiofalo B; Bruni S; Certelli C; Sperduti I; Baiocco E; Vizza E
Minerva Med; 2019 Aug; 110(4):330-340. PubMed ID: 31081304
[TBL] [Abstract][Full Text] [Related]
33. Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?
Mysona DP; Ghamande S; She JX; Tran L; Tran P; Rungruang BJ; Chan JK; Bae-Jump V; Gehrig PA
Ann Surg Oncol; 2021 Jul; 28(7):3605-3615. PubMed ID: 33155151
[TBL] [Abstract][Full Text] [Related]
34. Management of advanced ovarian cancer in Leicester: The benefits of a paradigm shift in surgical approach.
Barakat A; Ismail A; Chattopadhyay S
J Obstet Gynaecol Res; 2022 Dec; 48(12):3233-3241. PubMed ID: 36151704
[TBL] [Abstract][Full Text] [Related]
35. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
36. What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
Chiva L; Lapuente F; Castellanos T; Alonso S; Gonzalez-Martin A
Ann Surg Oncol; 2016 May; 23(5):1666-73. PubMed ID: 26714955
[TBL] [Abstract][Full Text] [Related]
37. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
38. Clinical auditing as an instrument to improve care for patients with ovarian cancer: The Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS; van Driel WJ; van Ham M; Wouters MW; Kruitwagen R;
Eur J Surg Oncol; 2021 Jul; 47(7):1691-1697. PubMed ID: 33581966
[TBL] [Abstract][Full Text] [Related]
39. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
40. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
